Should chronic hepatitis B be treated as early as possible?

International Journal of Technology Assessment in Health Care

Volumn 29, Issue 1, 2013, Pages 35-41

  Hulstaert, Frank ^a   Schwierz, Christoph ^a   Nevens, Frederik ^b   Thiry, Nancy ^a   Gamil, Mohamed ^b   Colle, Isabelle ^c   Van De Sande, Stefaan ^a   Horsmans, Yves ^d  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Antiviral treatment; Chronic hepatitis B; Cost effectiveness analysis; Cost utility analysis; Entecavir; Natural disease progression; Quality of life; Tenofovir

Indexed keywords

ANTIVIRAL TREATMENTS; CHRONIC HEPATITIS B; COST EFFECTIVENESS ANALYSIS; COST-UTILITY ANALYSIS; DISEASE PROGRESSION; ENTECAVIR; QUALITY OF LIFE; TENOFOVIR;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS; COSTS; MARKOV PROCESSES; QUALITY CONTROL;

PATIENT TREATMENT;

ENTECAVIR; TENOFOVIR;

ADULT; ARTICLE; BELGIUM; CHRONIC HEPATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; BELGIUM; COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; GUANINE; HEALTH CARE SURVEYS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MARKOV CHAINS; MIDDLE AGED; ORGANOPHOSPHONATES; QUALITY OF LIFE; SECONDARY PREVENTION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874452722     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462312000736     Document Type: Article

References (25)

1. European Association for the Study of the Liver (EASL). Clinical Practice Guidelines:management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85
2. Horsmans Y, Thiry N, le Polain M, et al. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study. Health Technology Assessment (HTA). Brussels: Federal Healthcare Knowledge Centre (KCE). KCE reports 127C. [cited 2012 November 23]. Available from: Https://kce.fgov.be/ publication/report/cost- effectiveness-of-Antiviral-Treatment-of-chronichepatitis-b-in-belgium-part-; 2010
3. Colombo M. Does chemotherapy preventHBV-related hepatocellular carcinomä Cons. Dig Liver Dis. 2010;42(SUPPL3):S298-301
4. Schwierz C, Thiry N, Van de Sande S, et al. Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium - Part 2. Health Technology Assessment (HTA). Brussels: Federal Healthcare Knowledge Centre (KCE). KCE reports 157C. [cited 2012 November 23]. Available from: Https://kce.fgov.be/publication/report/economic-evaluationof-Antiviral- Treatment-of-chronic-hepatitis-b-in-belgium; 2010
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52
6. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(Suppl):S45-55
7. Colle I, Adler M, Brenard R, et al. Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines. Acta Gastroenterol Belg. 2007;70:389-420
8. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26:937-49
9. Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: A cost-effectiveness analysis. Aliment Pharmacol Ther. 2008;27:1240-52
10. Arnold E, Yuan Y, Iloeje U, Cook G. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy. 2008;6:231-46
11. Orlewska E, Zammit D, Yuan Y, et al. The cost-effectiveness analysis of entecavir in the treatment of chronic hepatitis B (CHB) patients in Poland. Exp Clin Hepatol. 2008;4:20-8
12. Costa AMN, L 'italien G, Nita ME, Araujo ESA. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Braz J Infect Dis. 2008;12:368-73
13. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the costeffectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009;51:640-6
14. Veenstra DL, Sullivan SD, Lai M-Y, et al. HBeAg-negative chronic hepatitis B: Cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health. 2008;11:131-8
15. Lacey LF, Gane E. The cost-effectiveness of long-Term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat. 2007;14:751-66
16. Lacey L, Chien R-N, Chuang W-L, Pwu R-F. Economic evaluation of chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol. 2008;23:571-9
17. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13:922-33
18. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons. Value Health. 2008;11:527-38
19. Post SE, Sodhi NK, Peng C-H, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Affairs (Millwood). 2011;30:340-8
20. Veldhuijzen IK, Toy M, Hahne SJ, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology. 2010;138:522-30
21. Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis. 2011;52:1294-306
22. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-86
23. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73
24. Croagh CMN, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int. 2010;30:1115-22
25. Kobashi H, Miyake Y, Ikeda F, et al. Long-Term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res. 2011;41:405-16